The role of pattern recognition and autophagy in innate anti-bunyaviral immunity

模式识别和自噬在先天性抗布尼亚病毒免疫中的作用

基本信息

  • 批准号:
    10686406
  • 负责人:
  • 金额:
    $ 50.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-23 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Summary Innate immunity is the first line of defense against pathogens and is highly conserved from insects to humans. While many key facets of the innate immune system have been elucidated, there is a fundamental gap in our knowledge of the pathways that restrict arthropod-borne viral infections in the diverse target tissues that are infected during the infection of the mammalian host. Importantly, a molecular understanding of these mechanisms is essential to overcome the lack of effective antiviral therapeutics and combat human disease. The Drosophila immune response is highly homologous to that of vector insects and additionally shares striking similarities with mammalian innate immunity. Using the Drosophila system, we previously found that the emerging bunyavirus Rift Valley Fever virus (RVFV) is sensed by the Drosophila Pattern recognition receptor (PRR), Toll-7, which activates antiviral autophagy and that this is conserved in mammalian cells. We found that TLR2-dependent antiviral autophagy can control RVFV in some cell types while in other cells engagement of TLR2 leads to cell death. Moreover, we found that pharmacological activation of autophagy is restrictive against RVFV in mammalian primary neurons, suggesting that this pathway may be harnessed for antiviral protection. Since tissue-specific signaling of PRR pathways are poorly characterized we screened a panel of PRR agonists for those that could block RVFV infection in neurons and in non-neuronal cells in parallel. We identified two classes of antiviral PAMPs. First, we identified TLR2 agonists as antiviral in both cell types. Since pharmacological activation of autophagy can protect primary mammalian neurons from infection, we suggest that TLR2 activation may be harnessed to defend neurons from encephalitic viruses. Second, we identified Dectin-1 agonists as specifically antiviral in neurons which will be further explored. Therefore, the long-term objective of the proposed research is to understand the molecular mechanisms by which viral infections are sensed and controlled by innate pathways and how this may be harnessed to induce protective defenses in diverse cell types including neurons. To accomplish these goals, this application proposes two specific aims: (1) to identify the mechanism by which RVFV is sensed by TLR2 leading to diverse outcomes, autophagy or cell death; and (2) explore the PRR pathways that can control bunyaviruses in mature mammalian neurons.
总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sara Cherry其他文献

Sara Cherry的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sara Cherry', 18)}}的其他基金

Development and validation of antivirals against Flaviviruses
黄病毒抗病毒药物的开发和验证
  • 批准号:
    10514328
  • 财政年份:
    2022
  • 资助金额:
    $ 50.59万
  • 项目类别:
Defining the role of microbiota-derived cyclic dinucleotides in priming antiviral immune defenses.
定义微生物群衍生的环状二核苷酸在启动抗病毒免疫防御中的作用。
  • 批准号:
    10551893
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Small Molecule Screening to Identify Novel Sars-CoV-2 Therapeutics
通过小分子筛选鉴定新型 Sars-CoV-2 疗法
  • 批准号:
    10223018
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
Defining the role of microbiota-derived cyclic dinucleotides in priming antiviral immune defenses.
定义微生物群衍生的环状二核苷酸在启动抗病毒免疫防御中的作用。
  • 批准号:
    10326823
  • 财政年份:
    2020
  • 资助金额:
    $ 50.59万
  • 项目类别:
The role of pattern recognition and autophagy in innate anti-bunyaviral immunity
模式识别和自噬在先天性抗布尼亚病毒免疫中的作用
  • 批准号:
    10468096
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:
Small Molecule Screening to Identify Novel Sars-CoV-2 Therapeutics
通过小分子筛选鉴定新型 Sars-CoV-2 疗法
  • 批准号:
    10239297
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:
The role of pattern recognition and autophagy in innate anti-bunyaviral immunity
模式识别和自噬在先天性抗布尼亚病毒免疫中的作用
  • 批准号:
    9917158
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:
The role of pattern recognition and autophagy in innate anti-bunyaviral immunity
模式识别和自噬在先天性抗布尼亚病毒免疫中的作用
  • 批准号:
    10222526
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:
The role of pattern recognition and autophagy in innate anti-bunyaviral immunity
模式识别和自噬在先天性抗布尼亚病毒免疫中的作用
  • 批准号:
    10673509
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:
The role of pattern recognition and autophagy in innate anti-bunyaviral immunity
模式识别和自噬在先天性抗布尼亚病毒免疫中的作用
  • 批准号:
    10023159
  • 财政年份:
    2019
  • 资助金额:
    $ 50.59万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 50.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了